SCHEMBL4415044

SCHEMBL4415044

COc1ccccc1N1CCN(c2nc(NCCO)nc(NCCO)c2C#N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
MAPT P10636 8/20 0.53
MAPK1 P28482 4/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
THRB P10828 2/20 0.52
KDM4E B2RXH2 2/20 0.52
TP53 P04637 2/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
RAC1 P63000 1/20 0.52
HSD17B10 Q99714 1/20 0.52
DRD2 P14416 6/20 0.48
HTR1A P08908 4/20 0.48
HTR2A P28223 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415144 0.90 MAPT (0.55) NPC1MAPTMAPK1ALDH1A1MEN1
SCHEMBL4416390 0.87 KDM4E (0.43) NPC1MAPTALDH1A1MEN1KMT2A
SCHEMBL4414810 0.87 ALDH1A1 (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4427305 0.86 KDM4E (0.45) NPC1MAPTMAPK1ALDH1A1MEN1
SCHEMBL4416965 0.86 ALDH1A1 (0.43) NPC1MAPTMAPK1ALDH1A1MEN1
SCHEMBL4422707 0.85 GRM2 (0.45) GBA1
SCHEMBL4419664 0.85 MAPT (0.42) MAPTMAPK1ALDH1A1MEN1KMT2A
SCHEMBL4424088 0.84 GBA1 (0.46) NPC1MAPTMAPK1ALDH1A1MEN1
SCHEMBL4416905 0.82 ALDH1A1 (0.47) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4413464 0.81 RAB9A (0.41) MAPTALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397351-B1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
EP-1397351-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-17 EP disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 NPC1 1364/4885MAPT 1578/4885MAPK1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.